TransMedics Group (NASDAQ:TMDX) Receives "Overweight" Rating from Piper Sandler

TransMedics Group (NASDAQ:TMDX - Get Free Report)'s stock had its "overweight" rating reiterated by Piper Sandler in a research note issued on Wednesday,Benzinga reports. They presently have a $145.00 price target on the stock, up from their prior price target of $125.00. Piper Sandler's price target points to a potential upside of 4.28% from the company's previous close.

Several other equities analysts also recently commented on TMDX. Oppenheimer upped their price objective on shares of TransMedics Group from $125.00 to $130.00 and gave the company an "outperform" rating in a research note on Friday, May 9th. Canaccord Genuity Group reissued a "buy" rating and issued a $104.00 price target on shares of TransMedics Group in a research note on Tuesday, March 11th. Finally, Needham & Company LLC reissued a "hold" rating on shares of TransMedics Group in a research note on Tuesday. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, TransMedics Group currently has a consensus rating of "Moderate Buy" and a consensus target price of $125.11.

TransMedics Group Trading Up 2.6%

Shares of NASDAQ:TMDX traded up $3.46 during midday trading on Wednesday, hitting $139.05. 783,703 shares of the stock traded hands, compared to its average volume of 1,362,820. The stock has a market capitalization of $4.70 billion, a PE ratio of 147.93 and a beta of 2.10. The business's 50 day moving average is $101.54 and its two-hundred day moving average is $80.28. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. TransMedics Group has a one year low of $55.00 and a one year high of $177.37.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.29 by $0.41. The firm had revenue of $143.54 million during the quarter, compared to the consensus estimate of $123.39 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The company's quarterly revenue was up 48.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.35 earnings per share. As a group, research analysts forecast that TransMedics Group will post 1 earnings per share for the current year.

Insiders Place Their Bets

In other TransMedics Group news, Director David Weill sold 732 shares of the company's stock in a transaction dated Friday, May 23rd. The shares were sold at an average price of $123.88, for a total value of $90,680.16. Following the sale, the director now owns 12,134 shares in the company, valued at approximately $1,503,159.92. This represents a 5.69% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Edward M. Basile sold 5,000 shares of the stock in a transaction that occurred on Tuesday, May 27th. The shares were sold at an average price of $126.45, for a total transaction of $632,250.00. Following the sale, the director now owns 2,866 shares in the company, valued at approximately $362,405.70. The trade was a 63.56% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 11,732 shares of company stock worth $1,416,710. 7.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On TransMedics Group

A number of institutional investors have recently made changes to their positions in TMDX. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of TransMedics Group by 244.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,113,082 shares of the company's stock valued at $209,448,000 after buying an additional 2,209,996 shares during the last quarter. Braidwell LP purchased a new stake in shares of TransMedics Group during the fourth quarter valued at approximately $57,493,000. Norges Bank purchased a new stake in shares of TransMedics Group during the fourth quarter valued at approximately $22,861,000. Mackenzie Financial Corp grew its holdings in shares of TransMedics Group by 73.0% during the fourth quarter. Mackenzie Financial Corp now owns 828,147 shares of the company's stock valued at $51,635,000 after buying an additional 349,403 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in shares of TransMedics Group by 1,565.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 269,825 shares of the company's stock valued at $16,820,000 after buying an additional 253,624 shares during the last quarter. Hedge funds and other institutional investors own 99.67% of the company's stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.